

CONTENTS

	Page
ACKNOWLEDGEMENTS	iii
ABBREVIATIONS	v
TABLE OF CONTENTS	vii
LIST OF TABLES	xiv
LIST OF FIGURES	xvi

CHAPTER 1

INTRODUCTION	1-81
1.1. History	1
1.2. Relationship between Vehicle and Drug ...	5
1.3. Routes of Percutaneous Absorption ...	10
a. Transepidermal absorption ...	16
b. Absorption through appendages ...	19
1. Piloosebaceous apparatus ...	19
2. Sweat duct ...	20
1.4. Factors Influencing Percutaneous Absorption ...	21
a. Skin condition ...	21
b. Skin age ...	25
c. Regional skin sites ...	26
d. Species differences ...	28
e. Circulatory effect ...	31
f. Skin metabolism ...	32
g. Thermodynamic properties of drug ...	33
h. Effect of moisture ...	34
i. Effect of temperature ...	39
j. Effect of vehicle ...	40

	Page
k. Effect of pH ...	43
l. Effect of concentration of medicament..	44
m. Effect of surfactants ...	45
n. Miscellaneous factors ...	53
1.5. Classification of Bases ...	53
a. Hydrocarbon bases ...	53
b. Fats and fixed oil bases ...	56
c. Silicones ...	56
d. Absorption bases ...	57
e. Emulsion bases ...	58
f. Water-washable bases ...	61
2. RESEARCH ENVISAGED ...	63
3. PLAN OF WORK ...	67
REFERENCES ...	69

CHAPTER 2

MATERIALS AND METHODS ...	84-130
2.1. Materials and their Suppliers ...	84
2.2. Salient Properties of Selected Drugs ...	87
a. Mechanism of action ...	88
b. Uses ...	89
c. Absorption and fate ...	90
d. Adverse effect of corticosteroids ...	91

		ix
		Page
2.3. Review of Method of Analysis	...	94
a. Spectrophotometric methods	...	94
b. Polarographic analysis	...	97
c. Fluorescence analysis	...	98
d. Chromatographic analysis	...	99
1. Paper chromatographic analysis	...	99
2. Thin layer chromatography	...	100
3. Column chromatographic analysis	...	101
4. High pressure liquid chromatography	...	102
5. Gas chromatography	...	105
2.4. Miscellaneous	...	105
2.5. Methods of Analysis	...	107
a. Triamcinolone acetonide	...	108
b. Betamethasone 17-valerate	...	111
c. Maltcinonide	...	113
d. Fluocinolone acetonide	...	116
2.6. Interference Studies	...	118
2.7. Results and Discussion	...	120
REFERENCES	...	121

CHAPTER 3

FORMULATION, PRELIMINARY SCREENING AND RHEOLOGICAL STUDIES	...	131-136
3.1. Experimental Procedure	...	131
3.2. First Screening Evaluation	...	132
3.3. Second Screening Evaluation	...	132

		x
		Page
3.4. Third Screening Evaluation	...	145
a. Consistency study	...	146
b. Penetration study	...	147
c. Spreadability	...	151
3.5. Rheology of Bases	...	154
a. Rheological measurements	...	158
3.6. Results and Discussion	...	186
REFERENCES	...	195

CHAPTER 4

<u>IN VITRO</u> EVALUATION OF CORTICOSTEROID CREAMS	...	197-247
4.1. Literature Survey	...	197
4.2. Release Methods without a Rate-Limiting Membrane	...	203
a. Chemical and physical	...	204
b. Microbiological	...	207
4.3. Release Methods with a Rate-Limiting Membrane	...	209
a. Chemical and physical	...	209
1. Simulated skin membrane	...	209
2. Natural skin membrane	...	212
3. Diffusion cells : zero-order steady state flux	...	213
4. Diffusion cells : simulation of <u>in vivo</u> conditions	...	215
b. Microbiological	...	216
4.4. Preparation of Creams	...	217

	xi
	Page
4.5. Drug Release Studies ...	219
a. Experimental procedure ...	220
4.6. Drug Releasing Efficiency ...	226
4.7. Liberation of Active Ingredients from Sartorius Ointment Chamber Assembly ...	229
a. Description of the apparatus ...	229
1. Basic instrument ...	230
2. The container h_1 and h_2 for the aqueous phases 1 & 2 ...	230
3. The diffusion chamber (Type A) ...	230
b. Experimental procedure ...	231
4.8. Results and Discussion ...	235
REFERENCES ...	243

CHAPTER 5

BIOAVAILABILITY OF CORTICOSTEROID CREAMS ...	248-300
5.1. <u>In Vivo</u> Methods ...	248
a. Animal models ...	249
b. Techniques ...	250
1. Observation of a physiological or pharmacological response ...	250
2. Physical properties of the skin ...	251
3. Analysis of body tissues or fluids ...	251
4. Surface loss ...	253
5. Histology ...	253

5.2. Bioassay for Topical Steroids	...	254
a. Antigranuloma	...	255
b. Thymus involution	...	255
c. Inflammation	...	255
1. Croton oil	...	256
2. Mustard oil and Nitric acid	...	257
3. Tetrahydrofurfural alcohol	...	257
4. Kerosene	...	258
5. Lipopolysaccharide	...	258
6. Histamine	...	258
7. Experimentally produced eczematous reactions	...	259
8. Tape stripping	...	260
9. Erythema	...	260
d. Cytological techniques	...	261
1. Fibroblast inhibition	...	262
2. Reduction of mitotic rate	...	263
3. Skin thinning	...	263
4. Inhibition of hair growth	...	264
5. Leukocyte challenge	...	264
e. Psoriasis bioassay	...	265
f. The vasoconstrictor test	...	265
1. Development of a standard vasoconstrictor test	...	266
2. Design consideration for the vasoconstrictor test	...	267
3. The Barry-Woodford vasoconstrictor test - occluded	...	271
4. The Barry-Woodford vasoconstrictor test - Non occluded	...	272

Page

5. Precision and reproducibility of Barry-Woodford vasoconstrictor test	...	273
6. Dose-response relationships in the vasoconstrictor test	...	273
5.3. Bioavailability of Corticosteroid Creams...		274
a. Experimental	...	274
5.4. Primary Skin Irritation Study	...	282
a. Experimental	...	284
5.5. Results and Discussion	...	286
REFERENCES		291

CHAPTER 6

STABILITY AND MICROBIAL CONTAMINATION STUDIES	...	301-329
6.1. Experimental	...	303
a. Identification of related foreign steroids	...	309
6.2. Microbial Contamination	...	309
a. Aerobic microbial count	...	313
1. Direct transfer procedure	...	313
b. Gas formers and pathogenic organisms	...	314
1. Gas formers	...	314
2. Test for Salmonella	...	314
3. Test for Pseudomonas	...	314
6.3. Results and Discussion	...	324
REFERENCES		328

CHAPTER 7

SUMMARY AND CONCLUSIONS	...	330-339
-------------------------	-----	---------